Langerhans cell Histiocytosis in Adults

Langerhans cell histiocytosis (LCH) in adults is a rare disorder that occurs when the body produces too many Langerhans cells (histiocytes), which are a type of white blood cell that helps fight infection. While Langerhans cells are found in normal, healthy people, there is an over-production and build-up of these cells which can lead to organ damage in adults with LCH.

LCH Overview

Langerhans cell histiocytosis (LCH) is a rare type of blood disease that belongs to the group called histiocytic disorders or histiocytosis. LCH was previously considered an inflammatory or autoimmune disease but was recognized as a blood cancer in 2008 by the World Health Organization. This was partly due to the discovery of cancer-causing DNA changes (mutations) in BRAF- and other genes in biopsy samples from most patients.

LCH can affect children as well as adults and occurs more commonly in children. Among adults (ages 18 and over), the average age at diagnosis of LCH is around 40 years. The exact incidence of LCH is unknown and is estimated at 1-2 new cases per million population per year in the US. The disease-causing cells of LCH (histiocytes) can involve any organ system of the body from head to toe, but commonly affect the bones, lung, skin, or pituitary gland. Apart from the strong association of smoking and lung LCH, the cause of other forms of LCH is unknown. However, it is not considered a hereditary or contagious disease. The discovery of BRAF and other mutations has revolutionized the care of patients with LCH, resulting in targeted treatments that have the ability to improve patient survival.

Types of LCH

LCH can have variable manifestations, ranging from single site to multiple sites of disease. A “lesion” is a term used commonly to describe the area of involvement with LCH, which can also simply be called a “tumor.” According to the latest recommendations for treatment of adults with LCH, it is classified into the following 4 groups:

  • Unifocal: Single site (lesion or tumor) involving any organ
  • Single-system pulmonary: Isolated lung involvement (predominantly smoking related)
  • Single-system multifocal: More than one spot (lesion or tumor) involving any organ
  • Multi-system: More than one organ/system involvement
According to most experts, Langerhans cell Histiocytosis (LCH) is currently classified as a rare cancer and as of 2021, the National Comprehensive Cancer Network published clinical guidelines for histiocytosis classifying LCH, ECD, and RDD as histiocytic neoplasms. However, this doesn't necessarily mean that all of the worrisome implications that come along with the term “cancer” are true of LCH for every patient; LCH and other histiocytic disorders have a wide spectrum of presentations.


Latest LCH Educational Webinar

Play Video

Signs & Symptoms

The symptoms of LCH depend on the number and degree of organ involvement. The following section discusses the frequency of organ manifestations and corresponding symptoms experienced by patients with LCH. It is important to note that not all organ manifestations may result in symptoms.

  • Bones (30-50%): LCH can involve any bones within the body, although most commonly involves the skull, teeth, spine, ribs, or hip bones. In bone, LCH can present as unifocal (one location) or multifocal (two or more locations) bone disease. Symptoms of bone involvement include pain or swelling of the head, jaw, back, or other bones of the body.
  • Skin (30-50%): Skin involvement mostly occurs in combination with other disease sites (multisystem) but can involve the skin alone in 10-20% of cases. It is most commonly seen as red or brown rash with formation of flakes or crusts, and often on the chest, back, belly, arms, legs, head, or groin region. Rarely, it can cause a rash or ulcers in the mouth or genitals (vagina, penis, anus). Symptoms of skin involvement include red or brown rash, bumps, ulcers.
  • Bone Marrow
    Low blood counts (red blood cells, white blood cells, platelets/clotting cells).
  • Lungs
    Chest pain, shortness of breath, collapsed lung, dry cough, weight loss, fatigue, loss of appetite, night sweats, coughing up blood.
  • Teeth/Gums
    Loosening or loss of teeth, swollen or bleeding gums, ulcerations, pain, swelling of face.
  • Ears
    Chronic ear infections, drainage/discharge, balance problems, bleeding, decreased hearing. Ear involvement can be a result of skull lesions expanding to the ear and may cause balance problems. Ear canals may be affected as part of the skin system, causing bleeding/drainage.
  • Endocrine System (pituitary gland/diabetes insipidus, hypothalamus, and thyroid gland)
    Excessive thirst, excessive urination, fatigue, sweats, temperature swings, weight gain, weight loss, nipple tenderness/discharge, menstrual problems in women, erectile dysfunction in men.
  • Female Genital/Reproductive Tract (vulva, vagina, cervix, ovaries)
    Inflammation, rash, and/or ulceration of the vulva, vagina, and/or cervix, but it may also affect the ovaries, causing dysfunction or failure of these organs.
  • Liver/Spleen/Lymph Nodes
    Swelling/tenderness of abdomen; enlargement of lymph nodes, spleen and/or liver; fatigue.
  • Gastrointestinal System (stomach or intestines)
    Diarrhea, nausea, vomiting, and/or weight loss.
  • Central Nervous System (spinal cord, brain lesions, pituitary gland)
    Staggering when walking, seizures, weakness of the arms, legs, or weakness of one side of the body. Since the pituitary gland could be affected, lesions of this system may also cause some of the same endocrine problems mentioned above.
  • Additional Non-specific Symptoms
    Fever, weakness, fatigue, chronic pain, weight loss, night sweats.

Pulmonary LCH (PLCH) can occur as part of multi-system disease, or it can occur alone. Nearly 20% of adults with PLCH have no presenting symptoms. An estimated 10%-15% of patients present with lung collapse as the first symptom, while others may show abnormalities in lung function tests. Dry cough and shortness of breath are the most common complaints, and weight loss, fever, sweats, and loss of appetite occur in approximately 33% of patients.

Many adults experience severe and sometimes overwhelming pain associated with this disease. While pain can be caused by bone lesions or bone defects that do not heal completely with therapy, it has also been observed that some patients have pain even when there is no active disease seen on x-ray. The cause of this pain is not understood; however, it is being currently explored in research. Pain is considered a complication of LCH that should be fully evaluated by a physician and treated with appropriate medications.

NCCN Guidelines Published in 2021

The National Comprehensive Cancer Network® (NCCN®) - an alliance of leading cancer centers - announced the publication of new NCCN Guidelines® for histiocytosis. These clinical practice guidelines provide the latest evidence and expert-consensus for diagnosing and treating the three most common forms of histiocytosis in adults: Langerhans cell histiocytosis (LCH), Erdheim-Chester Disease (ECD,) and Rosai Dorfman Disease (RDD). Although the guidelines are focused on adult patients, there may be insight for pediatric physicians as well. The Guidelines are listed as "histiocytic neoplasms" and can be found on NCCN's website.

You can find international expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults, here. You can download a copy, here. It is encouraged that you share this with your physicians for reference.

On November 1st, 2022, Memorial Sloan Kettering Cancer Center (MSK) announced that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms (HN). These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2, currently approved to treat melanoma. Gratitude and congratulations to the Principal Investigator of this study, Dr. Eli Diamond, neuro-oncologist and neurologist at MSK and Chair of the Scientific Committee for the Histiocytosis Association. We applaud the efforts of Dr. Diamond and the entire study team for this tremendous advancement. Read more here.

The diagnosis of LCH is made following a biopsy of the affected tissue. 

A small piece of the tissue is obtained so that it can be viewed under a microscope by a pathologist.  A diagnosis of Langerhans cell histiocytosis (LCH) is made following a biopsy and microscopic examination of the affected tissue. If the biopsy is positive for LCH, some other tests may be carried out to determine the extent of disease so that a treatment plan can be made. This procedure can be performed on any location but usually is done on the skin, bone, lymph nodes, liver, lung or bone marrow.

In addition, the following tests may be performed depending on particular symptoms:

  • Physical examination and history: Recording of height, weight, temperature, pulse, family history, history of symptoms, past illnesses, etc.
  • Neurological examination: Testing of ability to walk, muscle testing, coordination, and cognition.
  • Complete blood count (CBC): Checking levels of red blood cells, white blood cells, and clotting cells.
  • Blood chemistry tests: Studies for kidney, coagulation, thyroid and immune function; abnormal level can be a sign of disease. Complete blood count, sedimentation rate, liver function tests, electrolytes may be studied.
  • Liver function tests: Checking blood levels of substances released by the liver; an abnormal level can be a sign of disease in the liver.
  • Urinalysis: Testing the amount of red cells, white cells, protein and sugar in the urine.
  • Water deprivation test: Checks how much urine is made and whether it becomes concentrated when water is withheld; used when diabetes insipidus is suspected.
  • Bone marrow biopsy: The removal of bone marrow, blood and a small piece of bone by inserting a hollow needle into the hipbone; the sample is studied under a microscope to look for signs of LCH.
  • X-ray/Skeletal X-ray: Performed of the lungs or the bones to determine if there are abnormalities.
  • Bone scan: A scan for bone lesion in which a small amount of radioactive material is injected into a vein, collects in any abnormal parts of the bones and is shown on a scanner.
  • CT scan: For this x-ray dye may be injected into a vein or swallowed to help find any abnormalities; the scan takes a number of detailed pictures at different angles inside the body.
  • MRI: Using a substance called gadolinium injected into a vein to highlight areas of disease involvement, this scan then takes a number of detailed pictures inside the body.
  • PET scan: A small amount of radioactive sugar is injected into a vein, and diseased cells show up brighter on the scanner.
  • Ultrasound: High-energy sound waves are bounced off organs and tissue and make echoes, which form a picture of the internal body.
  • Endoscopy: When involvement of the digestive tract is suspected, a tube is passed into a body opening such as mouth or rectum to look at internal tissue; often, biopsies are also taken at the same time.

If there are symptoms of diabetes insipidus, a water-deprivation test should be done. When the bones near the ears or eyes are involved, a head CT scan is indicated. An MRI of the brain may be necessary if the lesions are near the eyes or ears or there is suspicion of central nervous system (CNS) involvement. Chest CT and lung function studies are performed when indicated. Other testing may be done, depending on symptoms. Other biopsies may be performed if test results or abnormal findings during the physical exam cause the physician to suspect involvement of another area.

When lung involvement is suspected, a chest x-ray is usually done and is abnormal in most patients. These abnormalities are subtle, can be easily missed, or can be mistaken for other diseases such as emphysema. The most common abnormality (in 70% to 90% of cases) is a reduced DLCO, which is a lung function test that measures the rate which carbon dioxide moves from the lung to the blood. The most sensitive diagnostic test is a high-resolution CT scan (HRCT), another type of x-ray, which can reveal lung cysts that are characteristic of LCH. It is possible to make a diagnosis with a bronchoalveolar lavage (BAL). The BAL is a medical procedure in which a tube is passed through the mouth or nose into the lungs, and fluid is squirted into part of the lung and then collected for examination. If the BAL and HRCT do not provide a diagnosis, then surgical lung biopsy may be necessary. In patients with diagnosed LCH in other areas of the body such as skin or bone, the diagnosis of lung involvement can be made if the HRCT shows findings consistent with pulmonary Langerhans cell histiocytosis (PLCH).

There is no established, widely agreed-upon treatment of LCH in general. It depends upon the individual patient and the extent and areas of involvement. Some patients have had success with vinblastine (chemotherapy) and steroids, while others have benefited from limited surgery, other chemotherapy agents such as 2-chlorodeoxyadenosine (2CdA) or methotrexate, and even low-dose external beam irradiation. Some patients may have limited involvement, which does not progress to other areas and may not need systemic treatment.

There are medications called “targeted therapies” which block the activity of genes with mutations in them. For example, there are medications that block mutations in BRAF specifically. In small clinical trials, these medicines have been very effective in treating LCH. These treatments should be considered for certain instances of LCH, such as severe cases or those for which other treatments have not been successful. Targeted treatments for genes other than BRAF are under investigation.

In cases of pulmonary LCH, an essential part of treatment is discontinuing cigarette smoking or smoking of illegal drugs. In some cases, this can lead to stabilization of symptoms and even improvement. There are no established guidelines for the treatment of PLCH; however, some patients are treated with steroids, while others may receive treatment with systemic chemotherapy agents such as vinblastine, 2-CdA, cyclophosphamide, methotrexate, and even thalidomide. A small number of patients develop severe and disabling lung disease and may require a lung transplant.

Even if it is determined that no treatment is necessary at the time of diagnosis, the physician will likely monitor the disease regularly to be sure that there is not further progression of the existing areas and that new areas of involvement can be detected and treated early. The ultimate goal of an overall treatment plan, of course, is to use as little treatment as possible to keep the disease under control to preserve quality of life and prevent the histiocytosis from damaging vital organs.

Permanent Consequences

More recent advances in research and treatment of histiocytic disorders have provided a high survival rate for patients with this disease. At the same time, as more patients have been followed long-term, the risk for permanent consequences has become more obvious. It is now known that survivors can have significant consequences related to the disease and/or its treatment, sometimes following long-term remission. Most of these issues tend to be directly related to sites of original disease involvement and may affect quality of life. It is believed that more than half of patients will develop permanent consequences.

Also known as “late effects,” some consequences such as neurologic symptoms may not show up until 10 or more years after diagnosis, while other consequences such as diabetes insipidus can occur when histiocytosis is diagnosed, or even before. For this reason, “permanent consequences” has been suggested as a better term than “late effects.” Although some consequences such as tooth loss, bone defects, and scarring of the skin may be the result of surgical treatment, it is believed that the disease process itself is responsible for most of the effects.

Permanent consequences occur more often with multisystem patients but are also seen in patients with single-system disease at diagnosis. In one study, over 70% of multisystem LCH patients had one or more permanent consequences, compared to 24% of single-system patients. Children are more at risk to develop consequences because the disease can interfere with growth and development, and the consequences have a longer time to develop.

Some examples of permanent consequences include:

  1. Diabetes insipidus (DI)
  2. Stunted growth/failure to achieve sexual maturity
  3. Defects of bone/skull defects/facial asymmetry
  4. Loss of spinal height
  5. Loss of teeth/part of jawbone
  6. Bulging of the eyes
  7. Hearing loss
  8. Scarring of the skin
  9. Scarring of the liver
  10. Scarring of the lung
  11. Secondary cancers
  12. Neurologic/cerebellar problems, which can include:
    • Poor coordination/difficulty walking
    • Bad handwriting
    • Tremor/abnormal eye movements
    • Difficulty with balance/unsteadiness/clumsiness
    • Problems with speech and/or swallowing
    • Loss of short-term and/or long-term memory
    • Learning difficulty/poor school performance
    • Difficulties with concentration/attention/processing
    • Lower IQ score
    • Organizational difficulties
    • Behavior changes including aggression, eating disorders, depression, and difficulties with interpersonal relationships

The exact incidence of diabetes insipidus (DI) is not known, but it is believed to be in the range of 5% to 50% of LCH patients, depending on the location and extent of disease. The risk of developing DI in patients with multisystem LCH is 4 to 6 times greater than those with single-system disease. Patients with skull, facial, and/or eye bone lesions are at much higher risk of developing DI, and this risk is increased further if the disease remains active for a longer period or if it recurs. Although once established, diabetes insipidus cannot be cured, it can be successfully treated with a hormone called DDAVP.

Stunted growth is the most common endocrine abnormality and occurs in approximately 10% of children with histiocytosis. It was shown in one study to occur in 43% of patients who had diagnoses of both LCH and diabetes insipidus. Stunted growth can be successfully treated with daily injections of growth hormone, usually for as long as the child is growing. This treatment appears to be safe and effective and is not associated with an increased risk of disease reactivation.

Orthopedic problems from lesions of the spine, leg bones, and arm bones are one of the more common consequences and may be seen in 20% of patients. These problems include collapse of the vertebrae, instability of the spine that may lead to abnormal spinal curvature, decreased spinal height, fractured bones, and inequality of leg length. In addition, since the skull and facial bones are frequent sites of lesions, abnormalities and asymmetry of the face may occur. Some bone/facial abnormalities can be corrected by orthopedic or cosmetic surgery.

Dental problems with loss of teeth have been a significant problem for some patients, either directly related to disease affecting the jaw or related to aggressive surgery for jaw disease. The potential for restoration/cosmetic repair can be discussed with a knowledgeable physician. Residual eye bulging can affect one or both eyes. Hearing loss was found in one study to affect 16% of children treated for LCH. Of those with CT or MRI abnormalities of the mastoid, 59% had hearing loss. Inner ear involvement has been known to cause loss of balance. Hearing aids or surgically inserted electronic hearing devices (cochlear implants) may be necessary.

Liver disease may lead to scarring and destruction of the liver and, in rare cases, liver failure which may require transplantation. Lung disease is believed to occur in less than 10% of patients, causes scarring and damage of lung tissue, and can result in long-term poor lung function with a higher risk for infections, shortness of breath, and lung collapse. In cases of severe damage, a lung transplant may be necessary for survival. Permanent damage, however, is less common in children, whose lung tissue can more easily regenerate. Patients with a history of lung involvement may have a lifelong susceptibility to lung disease associated with cigarette smoking.

Patients with histiocytosis have a slightly higher chance of developing secondary cancers when compared to the unaffected population; secondary cancers could include leukemia, brain tumors, and cancer of the lung, liver, bone, lymph nodes, and eyes. It has not been determined whether this is caused by treatment or a genetic predisposition. Cancer can occur at the same time as histiocytosis or can occur years afterwards.

Neurologic problems with cognitive deficits, behavioral disturbances, and neuromotor dysfunction, also known as central nervous system (CNS) involvement, are reported to affect at least 10% of all LCH patients (19% of all multisystem patients). (For other histiocytic disorders, studies of greater numbers of patients are necessary to better define how often this occurs.) It is believed that this phenomenon is more frequently recognized now that more patients with histiocytosis are being followed long-term. It is characterized by symptoms in the brain that may not manifest until 10 or more years after initial diagnosis. Although this is usually seen on MRI scans, it may occur when there are no abnormal findings on MRI. The CNS complications can remain stable for years or can be progressive and become debilitating. No effective treatment has yet been developed; however, various forms of rehabilitation and teaching assistance can be helpful for these patients. These include assistance with learning and life skills; education about permanent consequences; teaching of repetition, reinforcement, and organizational skills; and placement of school/job accommodations. While the neurologic issues cannot be reversed, caregivers can provide tools that will help the patient increase his/her level of success.

In addition to compromised physical/cognitive function, histiocytosis survivors may experience quality-of-life issues such as anxiety/fear about possible relapse, sadness, anger, and depression. These feelings may be especially strong before follow-up visits, on illness-related anniversaries, or with onset of symptoms not related to the disease. For many people, these feelings will go away over time, while others may need psychological or psychiatric support. Finding a supportive network of other histiocytosis survivors can also be helpful.

  • On-line: You can subscribe to receive our emails so that you receive our newsletters, and you will also receive important announcements regarding the latest information and research developments on the histiocytic disorders. The Association also maintains a Facebook page and private Facebook group for families and patients with this disease.
  • Local support: The hospital where you or your child is being treated may have a support group for survivors of histiocytic disorders, rare diseases in general, or even cancer. Establishing face-to-face relationships with others going through similar experiences can be helpful.

Because of the possible impact of permanent consequences on school/job performance, ability to lead an independent life, and overall quality of life, it is important that the patient be evaluated and followed long term, especially those with multisystem disease. Early recognition of any deficit will be important, so that appropriate rehabilitation and assistance can be planned and put into place.

After years of research and discussion among researchers, there are still considerable gaps in the understanding of histiocytosis and its neurological complications. Some authorities believe it is a process separate from disease activity, and others believe that early, effective therapy may prevent or reduce the complications.

In order to make further progress in this field, the Histiocyte Society has developed a clinical trial/study called LCH-IV which opened for registration in 2012 and is on-going. This includes new guidelines for diagnosis and treatment of CNS LCH, including repeated MRIs, standardized neurologic evaluation, and neuropsychological tests for all patients with CNS disease. The study will test whether longer therapy for active disease will reduce the rate of reactivation and development of complications. You may consult your health care provider to find out about possible treatment options.

If you are a histiocytosis survivor with permanent consequences, it will be important to educate yourself about available resources and stay updated about the latest research findings. This information will help you make informed decisions and play an active role in acquiring the best support and services available. In doing so, you will create the best chance for a successful outcome.


What Do I Do Now?

A new diagnosis of Langerhans cell histiocytosis (LCH) can bring feelings of being overwhelmed, bewildered, scared, angry, sad, disappointed, helpless, and sometimes even feelings of guilt.  It is a time filled with unknowns, change, and new people and situations.  Most patients feel ill-equipped to understand what is happening to them and how to navigate through the illness to recovery.  There are, however, strategies and resources that can help you and your family get through the uncertain times that lie ahead.  One step at a time, you can gather information, create a support system, learn how to cope with stress, and become a strong self-advocate and part of the medical team.  The following tips and suggestions are provided to help guide you through this journey toward recovery.

Articles and Links



Printable Fact Sheets

Learn more about the different types of histiocytic disorders from these helpful fact sheets. Printing these for family and friends is a quick and easy way to teach them about the disease. More extensive information can be found in the Disease Information section of our website.

Choose from the following Fact Sheets: